Resumen
Objective: Metabolomic studies suggest plasma levels of bile acids (BAs) are elevated amongst subjects with non-alcoholic fatty liver disease (NAFLD) compared to healthy controls. However, it remains unclear whether or not specific BAs are associated with the clinically relevant transition from nonalcoholic fatty liver (i.e. simple steatosis) to non-alcoholic steatohepatitis (NASH), or enhanced progression of hepatic fibrosis, or genetic determinants of NAFLD/NASH. Methods: Among sequential subjects (n=102) undergoing diagnostic liver biopsy, we examined the associations of a broad panel of BAs with distinct histopathological features of NAFLD, the presence of NASH, and their associations with genetic variants linked to NAFLD and NASH. Results: Plasma BA alterations were observed through the entire spectrum of NAFLD, with several glycine conjugated forms of the BAs demonstrating significant associations with higher grades of inflammation and fibrosis. Plasma 7-Keto-DCA levels showed the strongest associations with advanced stages of hepatic fibrosis [odds ratio(95% confidence interval)], 4.2(1.2-16.4), NASH 24.5(4.1-473), and ballooning 18.7(4.8-91.9). Plasma 7-Keto-LCA levels were associated with NASH 9.4(1.5-185) and ballooning 5.9(1.4-28.8). Genetic variants at several NAFLD/NASH loci were nominally associated with increased levels of 7-Keto- and glycine-conjugated forms of BAs, and the NAFLD risk allele at the TRIB1 locus showed strong tendency toward increased plasma levels of GCA (p=0.02) and GUDCA (p=0.009). Conclusions: Circulating bile acid levels are associated with histopathological and genetic determinants of the transition from simple hepatic steatosis into NASH. Further studies exploring the potential involvement of bile acid metabolism in the development and/or progression of distinct histopathological features of NASH are warranted.
| Idioma original | English |
|---|---|
| Número de artículo | 154457 |
| Publicación | Metabolism: Clinical and Experimental |
| Volumen | 116 |
| DOI | |
| Estado | Published - mar 2021 |
Nota bibliográfica
Publisher Copyright:© 2020 Elsevier Inc.
Financiación
This work is supported by grants from the NIH and Office of Dietary Supplements ( P01 HL147823 , R01 HL103866 , R01 HL126827 , R01 DK120679 , P50 AA024333 , R01 HL133169 , R01 HL148110 , U01 DK061732 , R01 GM119174 , DP1 DK113598 ) and the Leducq Foundation (17CVD01). Mass spectrometry studies were performed on instrumentation supported in part through a Shimadzu Center of Excellence award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
| Financiadores | Número del financiador |
|---|---|
| National Institutes of Health (NIH) | |
| National Heart, Lung, and Blood Institute (NHLBI) | R01HL103866 |
| Office of Dietary Supplements | R01 DK120679, R01 HL126827, R01 HL133169, P50 AA024333, U01 DK061732, R01 GM119174, R01 HL148110, DP1 DK113598, P01 HL147823 |
| Fondation Leducq | 17CVD01 |
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
-
Good health and well being
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Huella
Profundice en los temas de investigación de 'Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver